



## SINGAPORE O&G LTD.

(Company Registration No. 201100687M)

FOR IMMEDIATE RELEASE

### SOG sees year-on-year growth on higher patient load

- Net profit and revenue for Q3 2019 grew 0.9% and 14.9% respectively

#### *Financial highlights for the period ended 30 September 2019*

(S\$'000)	Q3 2019	Q3 2018	Change (%)	9M 2019	9M 2018	Change (%)
Revenue	<b>10,409</b>	9,063	14.9	<b>29,059</b>	25,895	12.2
Profit from operations	<b>3,540</b>	3,437	3.0	<b>9,345</b>	10,732	(12.9)
Profit before tax	<b>3,546</b>	3,454	2.7	<b>9,302</b>	10,781	(13.7)
Profit for the period	<b>2,923</b>	2,896	0.9	<b>7,750</b>	9,125	(15.1)
Basic earnings per share (Singapore cents)	<b>0.61</b>	0.61	-	<b>1.63</b>	1.91	(14.7)

**SINGAPORE – 13 November 2019 - Singapore O&G Ltd.** (“SOG”, the “Company” or collectively with its subsidiaries, the “Group”), today announced net profit growth of 0.9% to S\$2.9 million for the third quarter ended 30 September 2019 (“Q3 2019”), on the back of revenue increasing 14.9% to S\$10.4 million for the same period.

The year-on-year (“YoY”) growth for the quarter was attributable to higher patient load at its Obstetrics & Gynaecology (“O&G”) and Cancer-related segments, which saw revenue growing S\$0.1 million and S\$0.2 million respectively. Paediatrics segment also registered S\$1.0 million increase in revenue on contributions from two new Paediatrics clinics which commenced operations in November 2018 and February 2019.

With the opening of four new clinics in 2018 and 2019, two Paediatrics, one Dermatology and one O&G, and an increase in staff headcount, the Group registered higher operating expenses in Q3 2019. Consumables and medical supplies used in Q3 2019 increased 26.3% YoY to S\$1.7 million, while employee remuneration expense rose 22.3% YoY to S\$4.1 million.

For the nine months ended 30 September 2019 (“9M 2019”), revenue rose 12.2% to S\$29.1 million compared to S\$25.9 million during the same period in 2018.

The Group continues to maintain a healthy financial position with zero borrowings and total cash and cash equivalents as at 30 September 2019 increased to S\$22.2 million compared to S\$18.1 million a year ago.

“Notwithstanding the expected start-up cost of our two new paediatric clinics added in November last year and February this year, the Group is starting to register profit for this segment following two years of gestation period. Revenue for this segment continues to see healthy growth with higher patient load. Our O&G segment also delivered 4.4% more babies during the quarter compared to a year ago. With steady demand for our healthcare services, we will continue to look at expanding our medical specialists for our business segments,” said Dr. Ivan Lau, Chief Executive Officer of SOG.

---

### **ABOUT SINGAPORE O&G LTD.**

(“SOG” or collectively with its subsidiaries, the “Group”)

Established since 2011, SOG is a leading healthcare service provider dedicated towards delivering premier medical services to women’s and children’s health and wellness at affordable prices.

With a long and established track record in the Obstetrics and Gynaecology (“O&G”) segment in Singapore, which provides pre-pregnancy counselling, delivery, pregnancy and post-delivery care, the Group has expanded its spectrum of services to include gynaecological and breast cancer, skin and aesthetic treatments, and paediatrics.

The Group’s clinics, under its four operating segments of O&G, Cancer-related, Dermatology and Paediatrics, are strategically located throughout Singapore to provide easy access to its patients.

For more information, please visit SOG’s website at [www.sog.com.sg](http://www.sog.com.sg).

-----  
For media and analyst queries, please contact:

**August Consulting**

Tel: +65 6733 8873

Janice ONG, [janiceong@august.com.sg](mailto:janiceong@august.com.sg)

Avril LIM, [avrillim@august.com.sg](mailto:avrillim@august.com.sg)

---

*This press release has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”) in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalyst.*

## Singapore O&G Ltd.

---

*This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.*

*The contact person for the Sponsor is Ms. Jennifer Tan, Associate Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and Email: [sponsorship@ppcf.com.sg](mailto:sponsorship@ppcf.com.sg)).*